We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Immunoassay Detects Antibodies to HIV

By LabMedica International staff writers
Posted on 23 Dec 2010
A qualitative immunoassay detects antibodies to Human Immunodeficiency Virus 1 (HIV-1) in 60 seconds.

The test is designed for use with whole blood, finger-stick blood, or plasma specimens and uses flow-through rather than lateral-flow technology to reduce processing time.

The single-use rapid test known as INSTI HIV-1 also includes a "unique antigen construct" composed of recombinant proteins for HIV-1 (gp-41) and HIV-2 (gp-36). Clinical trial data showed minimum sensitivity and specificity of 99.8% and 99.5%, respectively, in finger-stick whole blood samples; HIV-1 was detected with 99.9% sensitivity and 100% specificity in venipuncture whole blood and plasma samples. As with all rapid HIV tests, positive findings must be confirmed before a diagnosis of HIV infection can be established.

The immunoassay is manufactured by bioLytical Laboratories, Inc, (Richmond, Canada). The test is intended for use by trained personnel in point-of-care and laboratory situations to aid in the diagnosis of HIV-1 infections. If multiple rapid HIV tests are available, this test is suitable for use in appropriate multitest programs. The assay is packaged as a kit containing INSTI membrane units, sample diluent, color developer and clarifying solution, and is available in point-of-care use packaging, or packaging suitable for laboratory use.

Niel Constantine, PhD, a professor at the University of Maryland, (Baltimore, MD, USA), said, "The unique antigen used in the INSTI assay is important because the HIV testing community appears to be headed toward a multi-rapid test algorithm in which we must deploy tests with different antigens, so bioLytical's use of a unique antigen satisfies that requirement".

The assay has been approved by the US Food and Drug Administration, (FDA, Silver Springs, MD, USA). The 60-second HIV test previously was approved for use in 56 other countries, including Canada and member states of the European Union.

Related Links:

bioLytical Laboratories
University of Maryland
FDA




Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
PlGF Test
Quidel Triage PlGF Test

Latest Microbiology News

Viral Load Tests Can Help Predict Mpox Severity
23 Dec 2010  |   Microbiology

Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
23 Dec 2010  |   Microbiology

Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
23 Dec 2010  |   Microbiology



PURITAN MEDICAL